Langmu Medical

Langmu Medical (朗目医疗) is a Chinese ophthalmic medical device company focused on minimally invasive glaucoma surgery (MIGS). Founded in 2020 by Peking University PhD Kan Min together with leading ophthalmologists, it positions itself as a source-innovation platform for precision ophthalmic treatment, building a full-stack capability across consumables, instruments, and surgical equipment, with a stated "clinically driven, medicine-engineering integration" philosophy. A Qiming Venture Partners portfolio company and a national-level high-tech enterprise, it announced in January 2026 the completion of a nearly 100 million RMB Series A round, with proceeds earmarked for clinical follow-up and registration filings of its core products, construction of an industrial production base, commercialization team building, and pipeline R&D . Founder-CEO Kan Min framed the round as the shift "from 0-to-1 technology validation to the 1-to-100 industrialization journey," with the goal of giving Chinese doctors homegrown high-end ophthalmic surgical tools . It was also named among Qiming portfolio companies on the 2025 China Future Unicorn Top 100 list .